Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Xuejun Victor Peng"'
Autor:
Leah Shepherd, Neil Skolnik, Linong Ji, Terry Dex, Lawrence Blonde, Xuejun Victor Peng, Rory J. McCrimmon, Robert Lubwama, Angelo Avogaro, Anders H. Boss
Publikováno v:
Diabetes Therapy
Introduction Injectable therapies such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and basal insulin (BI) are well-established agents for people with type 2 diabetes (T2D). This study aimed to investigate real-world effectiveness of GLP-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33219d9ea10d4188441b6200b2577682
https://doi.org/10.1007/s13300-020-00905-y
https://doi.org/10.1007/s13300-020-00905-y
Autor:
Anders Hasager Boss, Julio Rosenstock, Lizheng Shi, Robert Lubwama, Xuejun Victor Peng, Francisco Javier Ampudia-Blasco, Vivian Fonseca
Publikováno v:
Diabetes, Obesity & Metabolism
Aim To assess the impact of the timing of initiating both basal insulin and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) on reaching glycaemic control targets over 6 and 12 months in people with type 2 diabetes (T2D) uncontrolled on or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f65328f653c1e5d0eb1addcdd5291830
https://doi.org/10.1111/dom.14154
https://doi.org/10.1111/dom.14154
Autor:
Yukiko Morimoto, Hiroshi Maegawa, Mike Baxter, Robert Lubwama, Masami Tamiwa, Masakatsu Hattori, Xuejun Victor Peng
Publikováno v:
Diabetes Therapy
Introduction:The effectiveness of basal insulin (BI) or glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in providing glycemic control in patients with type 2 diabetes (T2D) in Japanese routine practice is not well known. This real-world observa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2535534eeb4431dfc510203f2b35911
http://europepmc.org/articles/PMC7324466
http://europepmc.org/articles/PMC7324466
Autor:
Vivian Fonseca, Rajeev Ayyagari, Lizheng Shi, Priscilla Hollander, Xuejun Victor Peng, Eboni G. Price-Haywood, Robert Lubwama
Publikováno v:
Diabetes Therapy
Introduction When and how to intensify treatment in patients with type 2 diabetes (T2D) not achieving glycated hemoglobin (HbA1c) targets with oral antidiabetic drugs (OADs) in clinical practice remains a matter of clinical preference. This pilot stu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b033b1faafec924287935e9789d508f8
https://doi.org/10.1007/s13300-020-00783-4
https://doi.org/10.1007/s13300-020-00783-4
Autor:
Lawrence Blonde, Xuejun Victor Peng, Alka Shaunik, Rory J. McCrimmon, Anders H. Boss, Kyu Rhee, Supriya Kumar, Sidhartha Balodi, Claire Brulle-Wohlhueter, Luigi F. Meneghini
Publikováno v:
Diabetes Therapy
Introduction Basal insulin (BI) plays an important role in treating type 2 diabetes (T2D), especially when oral antidiabetic (OAD) medications are insufficient for glycemic control. We conducted a retrospective, observational study using electronic m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2114b7e020717a1610a09f0fe4dcc6f
https://pubmed.ncbi.nlm.nih.gov/29600507
https://pubmed.ncbi.nlm.nih.gov/29600507